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Massive parallel RNA sequencing of highly puriﬁed
mesenchymal elements in low-risk MDS reveals tissue-
context-dependent activation of inﬂammatory programs
Leukemia (2016) 30, 1938–1942; doi:10.1038/leu.2016.91
Myelodysplastic syndromes (MDS) have long been considered
hematopoietic-cell autonomous disorders in which disease initia-
tion and progression is exclusively driven by hematopoietic cell
intrinsic genetic events. Recent experimental ﬁndings have
challenged this view, implicating mesenchymal elements in the
bone marrow microenvironment in disease pathogenesis. Speci-
ﬁcally, genetic perturbation of mesenchymal cells has the ability to
induce MDS and acute myeloid leukemia, establishing an
experimental concept of ‘niche-induced’ oncogenesis.1,2 Alterna-
tively, primary alterations in hematopoietic cells have the ability to
alter mesenchymal niche components, such that niche cells
facilitate disease propagation in the context of xenograft
transplantation.3 Together, these observations challenge the view
that ineffective hematopoiesis and leukemic progression is
exclusively driven by hematopoietic-cell autonomous events in
human MDS. Translation of experimental ﬁndings to human
disease is complicated by a lack of insight in the molecular
wiring of primary, non-expanded mesenchymal cells in MDS.
Insights into the biology of mesenchymal elements in human
MDS and other hematopoietic disorders thus far have been
derived from studies investigating ex vivo-expanded
mesenchymal cells derived from the diseased bone marrow.
The hierarchic, biologic and molecular relationship between
these ex vivo-expanded cells and their in situ counterparts,
however, has remained largely unknown. Here we describe
massive parallel transcriptome sequencing of prospectively
isolated mesenchymal elements from human low-risk MDS
(LR-MDS), revealing a common molecular signature, distinct
from both normal and ex vivo-expanded cells, characterized
by cellular stress and upregulation of genes encoding
inﬂammation-associated secreted factors with established inhi-
bitory effects on hematopoiesis.
Mesenchymal cells were prospectively FACS-sorted (ﬂuores-
cence activated cell sorting) from bone marrow aspirates of
LR-MDS patients (n= 12, Supplementary Table S1) and normal
controls (n= 10) using previously established markers of primary
bone marrow mesenchymal cells (Figure 1a).4 The frequency
of CD45−/7AAD−/CD235a−/CD31−/CD271+/CD105+ mesenchymal
cells in LR-MDS was not signiﬁcantly different from normal bone
marrow (Figure 1b) (0.019 ± 0.0086% vs 0.022 ± 0.0066% of
mononuclear cells, P= 0.819 by unpaired Student’s t-test), and
these cells comprised a small subset of CD45−/7AAD−/CD235a−
‘niche’ cells (10.41 ± 4.086% vs 12.30 ± 5.052%, P= 0.771) with the
major constituent being CD31+ endothelial cells (43.80 ± 7.243%
vs 38.28 ± 9.424%, P= 0.816).
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Figure 1. Prospective isolation and molecular characterization of mesenchymal cells in LR-MDS. (a) Gating strategy to identify and
isolate 7AAD−/CD45−/CD235a−/CD271+/CD105+ mesenchymal cells. (b) Frequency of mesenchymal cells in normal and MDS samples.
(c–f) Transcriptional validation of the mesenchymal identity of 7AAD−/CD45−/CD235a−/CD271+/CD105+ cells, revealing differential expression
in comparison with endothelial subsets of (c) deﬁning cell surface markers (CD271, CD105 and CD31), (d) known mesenchymal markers
(CD73, CD90 and CD146), (e) established hematopoiesis-supporting cytokines (CXCL12, ANGPT1 and KITL) and (f) bone lineage markers
(BGLAP, RUNX2, SPP1 and ALPL). BM, bone marrow; FPKM, fragments per kilobase of exon per million fragments mapped; FSC-W,
forward scattered light-width; SSC-A, side scattered light-area; 7AAD (7-aminoactinomycin D); CD45 (PTPRC: protein tyrosine phosphatase,
receptor type, C); CD235a (Glycophorin A); CD271 (NGFR: nerve growth factor receptor); CD105 (ENG: endoglin); CD31 (PECAM-1: platelet/
endothelial cell adhesion molecule-1). CD73 (NT5E: ecto-5ʹ-nucleotidase); CD90 (THY1: Thy-1T-cell antigen); CD146 (MCAM: melanoma cell
adhesion molecule); CXCL12 (stromal cell-derived factor 1); ANGPT1 (angiopoietin 1); KITL (KIT ligand); BGLAP (osteocalcin); RUNX2
(runt-related transcription factor 2); SPP1 (osteopontin); ALPL (alkaline phosphatase, liver/bone/kidney). (c–f) Normal samples (n= 10); MDS
samples (n= 12). Black bar: CD271+ mesenchymal cells; white bar: CD31+ endothelial cells. FDR, false discovery rate. **FDRo0.01;
***FDRo0.001.
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RNA was extracted from highly puriﬁed mesenchymal elements
and complementary DNA synthesis was performed using the
SMARTer Ultra Low RNA kit for Illumina Sequencing (Clontech,
Mountain view, CA, USA) (Supplementary Methods). Quality of
RNA-sequencing data were shown to be similar for normal
and LR-MDS-derived samples using various quality parameters
including the number of aligned bases, base composition,
coverage coefﬁcient and full-length transcript coverage (from 5ʹ
end to 3ʹ end) reﬂecting no systematic 5ʹ-end or 3ʹ-end bias
(Supplementary Figure S1). The mesenchymal identity of
CD45−/7AAD−/CD235a−/CD31−/CD271+/CD105+ cells was con-
ﬁrmed molecularly by whole-transcriptome analysis
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demonstrating signiﬁcant abundance of transcripts encoding
deﬁning membrane proteins (Figure 1c), established markers of
mesenchymal stem cells (Figure 1d),4,5 essential ‘niche’ factors
governing the behavior of hematopoietic stem and progenitor
cells (Figure 1e), and osteolineage markers (Figure 1f) compared
with endothelial cells. Collectively, the ﬁndings demonstrate the
feasibility of prospective isolation and molecular characterization
of highly puriﬁed primary mesenchymal elements in LR-MDS by
massive parallel transcriptome sequencing.
Principal component analysis of all transcriptomes demon-
strated uniform clustering of normal mesenchymal cells, implying
transcriptional homogeneity (Figure 2a). Strikingly, distinct and
more heterogeneous clustering of mesenchymal transcriptomes
was found in LR-MDS, revealing that these cells are transcription-
ally distinct from their normal counterparts. Gene set enrichment
analysis (GSEA) was subsequently performed to deﬁne the molecular
networks underlying the distinct transcriptional landscape of
LR-MDS. Gene sets associated with inﬂammatory response and
cellular stress were remarkably enriched in LR-MDS (Figures 2b and
c; Supplementary Table S2). Cellular stress was reﬂected by a
reduced colony forming capacity of the CD271+ mesenchymal
population in LR-MDS to form colonies (Figure 2d) with morphologic
features reminiscent of cellular senescence (Figure 2e), as described
earlier for expanded stromal cells in LR-MDS.6,7 Distinct hierarchical
clustering and the signatures of cellular stress were not age-
dependent, as these signatures remained statistically signiﬁcant
when examined in an age-matched sub-cohort of patients and
controls (Supplementary Figure S2). Together, the data indicate
that mesenchymal cells in LR-MDS are molecularly and function-
ally distinct from their normal counterparts, characterized by
cellular stress, reﬂected by a reduced ex vivo capacity to form
ﬁbroblast colonies.
Thus far, molecular and biologic insights into the role of
mesenchymal cells in the pathogenesis of human MDS have been
derived from studies using ex vivo-expanded and plastic adherent
stromal cells. The molecular relationship between these expanded
cells and their in situ mesenchymal counterparts has remained
largely unknown. Elucidation of the transcriptome of mesenchy-
mal elements in the MDS marrow allows us to compare our
transcriptional data with sequencing data obtained from
expanded cells in an age-matched cohort of LR-MDS published
earlier (Supplementary Figure S3).3
Comparison of FDR-signiﬁcant differentially expressed tran-
scripts between the two data sets demonstrated limited overlap
(Figure 2f), suggesting distinct molecular wiring between the two
mesenchymal cell sources. To obtain insight into the biologic
processes underlying differential gene expression, GO (gene
ontologies) term analysis was performed focusing on cellular
biologic processes. To correct for potential experimental differences
affecting fragments per kilobase of exon per million fragments
mapped (FPKM) values, we normalized expression of all genes in
LR-MDS to the expression of the controls in the respective data sets
as detailed in the Supplementary Methods section. Normalized
expression was subsequently used to perform GO term analysis and
GSEA, comparing sorted with expanded cells.
25 GO terms were signiﬁcantly (FDRo0.25) enriched in primary
CD271+ mesenchymal cells (whereas no signatures were enriched
in the ex vivo-expanded mesenchymal cells), many of which (8/25)
reﬂected response to external stimuli, chemokine activity
and immune regulation (Figure 2g). Transcript abundance
analysis in CD271+ cells in comparison with their normal
counterparts indeed revealed a signiﬁcant upregulation of
numerous cytokines (Supplementary Table S3), including a large
number of inﬂammatory factors such as interleukin(IL)-6 and IL-8,
and a wide variety of factors previously demonstrated to be
negative regulators of hematopoiesis, in particular, erythropoiesis
and B-lymphopoiesis—cell lineages that are typically affected in
LR-MDS (Supplementary Table S3).
To obtain insight into the molecular pathways underlying
the biologic processes identiﬁed, transcriptional network
analysis (GSEA) was performed. This identiﬁed 504 gene sets that
were signiﬁcantly (FDRo0.25) enriched in primary-sorted LR-MDS
stromal cells, whereas 16 signatures were enriched in expanded
LR-MDS stromal cells. Again, gene signatures related to inﬂamma-
tion and cellular stress were enriched in CD271+ cells with a
remarkable abundance of signatures related to epidermal
growth factor (EGF), transforming growth factor beta (TGFβ) and
tumor necrosis factor (TNF) signaling (Supplementary Figure S4,
Supplementary Table S4).
Collectively, the data comprise, to our knowledge, the ﬁrst
comprehensive transcriptional network analysis of highly puriﬁed
mesenchymal elements directly isolated from the marrow in
human hematopoietic disease. They support the view that these
cells are intricately implicated in MDS disease pathogenesis,
stressing the relevance of considering the tissue context in
generating a comprehensive understanding of the disease. The
data further support the notion that inﬂammatory signaling is an
important pathophysiologic factor in LR-MDS and implicate the
mesenchyme in this process. Finally, the data complement
ﬁndings derived from ex vivo stromal cells in this disease revealing
preferential overexpression of inﬂammatory pathways and
secreted factors in FACS-puriﬁed CD271+ cells. This likely reﬂects
active cross talk with other cellular elements within the
inﬂammatory bone marrow environment in LR-MDS,8 eliciting or
maintaining these transcriptional programs, which may not be
fully appreciated in ex vivo cultures.
The ﬁnding that secretory programs implicated in negative
regulation of hematopoiesis are activated in CD271+ cells, may be
of particular relevance, given their close anatomical proximity with
CD34+ cells,9 potentially harboring the MDS initiating popu-
lation.10 The data warrant future investigations unraveling the
signaling between cellular elements in the MDS marrow driving
these secretory programs. We expect that elucidation of the
transcriptome of highly puriﬁed mesenchymal elements in MDS
will thus be a valuable resource to the community, instructing the
validation and discovery of novel pathophysiologic factors and
putative therapeutic targets.11
Figure 2. Mesenchymal cells in LR-MDS display a distinct molecular signature characterized by cellular stress and inﬂammation. (a) Principal
component analysis (PCA) on the transcriptomes of normal and LR-MDS mesenchymal cells. Patient numbers in a refer to LR-MDS patient IDs
(Supplementary Table S1). (b) Example of GSEA plot revealing inﬂammatory response in the mesenchymal cells from LR-MDS.
(c) Representative GSEA plot demonstrating deregulation of the gene set associated with cellular stress in response to UV in LR-MDS
mesenchymal cells. Gene set size, NES and FDR values of each gene set is listed. (d) Number of CFU-F colonies formed by normal (n= 3) or
LR-MDS (n= 3) CD271+ mesenchymal cells. (e) Representative images of cell clusters and colonies formed by mesenchymal cells from healthy
control (left panel) and LR-MDS patients (right panel). (f) Comparison of signiﬁcantly differentially expressed genes in FACS-puriﬁed CD271+
versus culture-expanded mesenchymal cells in LR-MDS. The total number of differentially regulated transcripts in each data set is indicated
and the overlapping differentially regulated genes in the two data sets are listed. (g) Biologic processes signiﬁcantly enriched (FDRo0.25) in
FACS-puriﬁed CD271+ LR-MDS mesenchymal cells in comparison with expanded stromal cells deﬁned by GO term analysis.**Po0.01.
CFU-F, colony-forming unit - ﬁbroblast; FDR, false discovery rate; NES, normalized enrichment score; UV, Ultraviolet.
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Gab2 is essential for Bcr-Abl-mediated leukemic
transformation and hydronephrosis in a chronic myeloid
leukemia mouse model
Leukemia (2016) 30, 1942–1945; doi:10.1038/leu.2016.92
Chronic myeloid leukemia (CML) is driven by the hyperactive
fusion kinase Bcr-Abl, resulting from a translocation between
chromosomes 9 and 22. Bcr-Abl organizes a multimeric protein
complex and activates various signaling pathways. In vitro
experiments have shown that one critical component of the
Bcr-Abl signaling complex is the docking protein Gab2, which is
coupled to Bcr-Abl via the Grb2 adaptor.1,2 These experiments
demonstrated that Gab2 ampliﬁes and channels Bcr-Abl signals to
the Shp2/Ras/ERK, PI3K/AKT/mTOR and JAK/STAT5 pathways.2
Gab2 was ﬁrst implicated in Bcr-Abl disease by retroviral
transduction experiments using bone marrow (BM) from Gab2-
deﬁcient (Gab2− /−) mice. These experiments revealed an essential
role of Gab2 for transformation by retrovirally expressed Bcr-Abl.3,4
In addition, we demonstrated that Gab2 confers resistance to
clinically approved Bcr-Abl inhibitors, including allosteric and third
generation inhibitors such as ponatinib.5–7 We also showed that,
in comparison with TKI-sensitive CML cells, the expression of this
docking protein is increased in myeloid cells from patients with
TKI-refractory disease5 or blast crisis,8 a stage known for its
insensitivity to Bcr-Abl inhibitors.
So far, the role of Gab2 in Bcr-Abl signaling has been only
studied in ex vivo or in bone marrow transplantation experiments
with retrovirally expressed Bcr-Abl.3–5 Using a Bcr-Abl transgene
CML model,9,10 we here analyze the in vivo role of Gab2 in a
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